- Charles River Labs has opened a new CRADL facility in Somerville, MA, co-located with Nest.Bio, to meet the increased demand for flexible vivarium and bench space.
- The new facility provides clients with a space to launch or expand their drug research programs, with access to Charles River’s portfolio of drug discovery and non-clinical development resources.
Charles River Labs has announced the opening of a new Charles River Accelerator and Development Lab (CRADL) facility in Somerville, MA. This facility is strategically co-located with Nest.Bio, a provider of rentable BSL-2 lab and office space. The new location on Chestnut Street is set to address an increased demand for more flexible vivarium and bench space, as well as on-demand in vivo study support services in the area.
Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River, expressed his excitement about the new facility. He said, “We are excited to bring CRADL to Somerville’s Brickbottom District, an emerging life science hub for biotech development in which startups unable to find lab space in the increasingly crowded Cambridge environment can thrive.”
The new CRADL facility provides a space for clients to launch or expand their drug research programs. It offers access to Charles River’s portfolio of drug discovery and non-clinical development resources. This combination of scalable contract vivarium space and Charles River’s extensive preclinical network supports clients in starting projects quickly, without the costly burden of building infrastructure.
The new Somerville facility offers private lab suites, rentable lab benches, and office space on the same floor. This arrangement provides an efficient and streamlined environment for both research and administrative functions. The facility is a testament to Charles River Labs’ commitment to supporting the growth of the life sciences sector and facilitating the work of researchers and biotech startups.
This move by Charles River Labs is a significant development in the contract manufacturing and CDMO landscape. It underscores the company’s commitment to providing flexible and accessible resources to support drug discovery and development.
Overview of outsourcing trends 
